Methods and compositions for modifying a single stranded target nucleic acid
The present disclosure provides compositions and methods for binding and/or cleaving a single stranded target nucleic acid. Subject compositions include a Cas9 polypeptide, a guide nucleic acid, and a PAMmer. A subject PAMmer is a single stranded oligonucleotide having a protospacer adjacent motif (PAM) sequence and at least one of: a specifity segment positioned 5′ of the PAM sequence, and an orientation segment positioned 3′ of the PAM sequence. In some embodiments, the Cas9 polypeptide is a variant Cas9 polypeptide having reduced nuclease activity relative to a corresponding wild type Cas9 polypeptide. In some cases, methods of binding are for visualizing single stranded target nucleic acids using a detectable label. In some cases, methods of binding are for isolating, collecting, and/or analyzing at least one of: (i) bound single stranded target nucleic acids; and (ii) polypeptides associated with bound single stranded target nucleic acids.
1. A method of binding a single-stranded-target RNA without cleaving the single-stranded target RNA, the method comprising:
contacting the single stranded target RNA with:
(a) a variant Cas9 polypeptide comprising one or more amino acid substitutions in the HNH domain such that the variant Cas9 polypeptide binds but does not cleave the single-stranded target RNA; and
(b) a guide nucleic acid that comprises: i) a first segment that comprises a nucleotide sequence that is complementary to a first target sequence in the single stranded target RNA; and ii) a second segment that forms a double-stranded RNA duplex and interacts with the variant Cas9 polypeptide,
wherein the first segment is 5′ of the second segment, and
wherein said contacting produces a variant-Cas9/target complex.
2. The method according to claim 1 , further comprising contacting the single-stranded target RNA with a PAMmer, wherein the PAMmer is a single stranded oligonucleotide comprising:
(a) a protospacer adjacent motif (PAM) sequence, and
(b) at least one of:
(i) an orientation segment, positioned 3′ of the PAM sequence, comprising a nucleotide sequence that is complementary to a second target nucleotide sequence in the single stranded target RNA; and
(ii) a specificity segment, positioned 5′ of the PAM sequence, comprising a nucleotide sequence that is complementary to said first target nucleotide sequence.
3. The method according to claim 2 , wherein the PAMmer comprises a detectable label.
4. The method according to claim 2 , wherein the PAMmer comprises the orientation segment and the specificity segment.
5. The method according to claim 1 , wherein the one or more amino acid substitutions are substitutions of one or both of an amino acid corresponding to H840 of SEQ ID NO:8 and D10 of SEQ ID NO:8.
6. The method according to claim 1 , wherein said one or more amino acid substitutions include at least one of:
(i) an H to A substitution at an amino acid position that corresponds to position H840 of SEQ ID NO: 8;
(ii) D to A and H to A substitutions at amino acid positions that correspond to position D10 and H840, respectively, of SEQ ID NO: 8.
7. The method according to claim 1 , wherein the variant Cas9 polypeptide comprises a detectable label.
8. The method according to claim 7 , wherein the detectable label of the variant Cas9 polypeptide is a directly detectable label.
9. The method according to claim 7 , wherein the detectable label of the variant Cas9 polypeptide is an indirectly detectable label.
10. The method according to claim 7 , wherein the detectable label is a fluorescent protein.
11. The method according to claim 7 , wherein the detectable label is a fluorescent dye.
12. The method according to claim 1 , wherein the guide nucleic acid comprises a detectable label.
13. The method according to claim 12 , wherein the detectable label of the guide nucleic acid is a directly detectable label.
14. The method according to claim 12 , wherein the detectable label of the guide nucleic acid is an indirectly detectable label.
15. The method according to claim 12 , wherein the detectable label of the guide nucleic acid is a nucleotide sequence that specifically binds a labeling protein.
16. The method according to claim 1 , wherein the variant Cas9 polypeptide comprises a fusion partner with an enzymatic activity, and wherein the single stranded target RNA is modified as a result of said contacting.
17. The method according to claim 1 , further comprising:
isolating the variant-Cas9/target complex;
releasing the single stranded target RNA from the variant-Cas9/target complex; and
collecting and/or analyzing the released single stranded target RNA and/or a polypeptide that may be associated with the single stranded target RNA.
18. The method according to claim 1 , wherein the target ssRNA is selected from: mRNA, rRNA, tRNA, non-coding RNA (ncRNA), long non-coding RNA (lncRNA), and microRNA (miRNA).
19. The method according to claim 1 , wherein the single stranded target RNA is a viral RNA.
20. The method according to claim 1 , wherein said contacting is in a cell in vitro or ex vivo.
21. The method according to claim 1 , wherein said contacting is in a cell in vivo.
22. The method according to claim 1 , wherein the guide nucleic acid is a single guide RNA.